Clene(CLNN) - 2024 Q3 - Quarterly Results

Exhibit 99.1 CLENE REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024 in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS and are awaiting meeting minutes ● Cash, cash equivalents and marketable securities of $14.6 million as of September 30, 2024 ● Amended debt agreement with Avenue Capital to defer principal payments and extend maturity of facility to second quarte ...